[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620725":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":36,"centralContacts":37,"locations":43,"responsibleParty":66,"collaborators":36,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":76,"sex":77,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":36,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":46,"whyStopped":36,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},{"fullName":5,"class":6},"Angitia Biopharmaceuticals","INDUSTRY",[8,14,18,22,26],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1 (Japanese)","EXPERIMENTAL","One of three single ascending dose cohorts of healthy Japanese participants. Participants will receive a single administration of low dose AGA2118.",[13],"Drug: AGA2118",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort 2 (Japanese)","One of three single ascending dose cohorts of healthy Japanese participants. Participants will receive a single administration of medium dose AGA2118.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Cohort 3 (Japanese)","One of three single ascending dose cohorts of healthy Japanese participants. Participants will receive a single administration of high dose AGA2118.",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Cohort 4 (Caucasian)","Healthy Caucasian participants will receive a single administration of high dose AGA2118.",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"Cohort 5 (Chinese)","Healthy Chinese participants will receive a single administration of high dose AGA2118.",[13],[31],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"DRUG","AGA2118","Participants will receive AGA2118 administered by subcutaneous injection",[9,15,19,23,27],null,[38],{"name":39,"role":40,"phone":41,"phoneExt":36,"email":42},"Kimberly Brown","CONTACT","818-862-2068","clinicaltrials@angitiabio.com",[44],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Los Angeles EPCU","RECRUITING","Glendale","California","91206","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-118.25508,34.14251,{"lat":56,"lon":55},[59,63],{"name":60,"role":40,"phone":61,"phoneExt":36,"email":62},"Stephanie Gill","888-228-7425","study.losangeles@parexel.com",{"name":64,"role":65,"phone":36,"phoneExt":36,"email":36},"Esther Yoon","PRINCIPAL_INVESTIGATOR",{"type":67,"investigatorFullName":36,"investigatorTitle":36,"investigatorAffiliation":36,"oldNameTitle":36,"oldOrganization":36},"SPONSOR","100620725","phase-1-a-phase-1-ethnobridging-trial-of-aga2118-in-healthy-japanese-chinese-and-caucasian-participants-atlas-100620725",false,"NCT07361354","A Phase 1 Ethnobridging TriaL of AGA2118 in Healthy Japanese, Chinese, and Caucasian ParticipantS (ATLAS)","A Phase 1, Randomized, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of AGA2118 in Healthy Japanese, Chinese, and Caucasian Participants","ATLAS","Inclusion Criteria:\n\n* Healthy males or females, aged 18 to 65 years\n* 25-hydroxyvitamin D ≥30 ng\u002FmL and agree to taking calcium and vitamin D supplements during the study\n* Meet the criteria for Japanese, Chinese, or Caucasian ethnicity\n\nExclusion Criteria:\n\n* Participating or have participated in another clinical trial within the past 6 months\n* Any bone fracture within the past 6 months\n* History of myocardial infarction or stroke within the past 12 months\n* Malignancy within the past 5 years\n* Current hyper- or hypocalcemia\n* Pregnant or breastfeeding women, or women planning to become pregnant during the study",true,"ALL","18 Years","65 Years",{"count":81,"type":82},30,"ESTIMATED","INTERVENTIONAL",[85],"PHASE1","This study will evaluate the effects of a single dose of AGA2118 in Japanese, Chinese, and Caucasian participants",[88,89],"Healthy Participants","Pharmacokinetic Study",[91,92],"Ethnobridging","Healthy volunteer","2026-01-16",{"date":95,"type":96},"2026-01-23","ACTUAL",{"date":98,"type":96},"2026-01-05",{"date":100,"type":82},"2026-11",{"name":102,"class":6},"Angitia Incorporated Limited",1]